# A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine

> **NCT05935033** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 38 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** Emraclidine

## Key facts

- **NCT ID:** NCT05935033
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-30
- **Primary completion:** 2025-02-21
- **Final completion:** 2025-02-21
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2025-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05935033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05935033, "A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Emraclidine". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT05935033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*